Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.
暂无分享,去创建一个
[1] Carmen Birchmeier,et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[2] J. Schneider,et al. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. , 2001, Seminars in oncology.
[3] B. Wörmann,et al. Trastuzumab and breast cancer. , 2001, The New England journal of medicine.
[4] K. Carraway,et al. Localization and modulation of ErbB receptor tyrosine kinases. , 2001, Current opinion in cell biology.
[5] Z. Qian,et al. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. , 2001, Life sciences.
[6] S. Reis,et al. Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity. , 2000, Circulation.
[7] B. Lorell,et al. Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. , 1999, Circulation.
[8] Yosef Yarden,et al. Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis , 1997, Neuron.
[9] D. O’Rourke,et al. Principles of receptor-based inhibition of erbB family receptor kinases: prospects for new therapies for human cancers. , 1997, Proceedings of the Association of American Physicians.
[10] M. Provinciali,et al. Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA , 1997, Cancer Immunology, Immunotherapy.
[11] S. Burden,et al. Neuregulin receptors, erbB3 and erbB4, are localized at neuromuscular synapses. , 1995, The EMBO journal.
[12] Kuo-Fen Lee,et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.
[13] Rüdiger Klein,et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.
[14] Carmen Birchmeier,et al. Multiple essential functions of neuregulin in development , 1995, Nature.
[15] D. Slamon,et al. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. , 1992, Cancer research.
[16] Y. Yarden,et al. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[17] A. Ullrich,et al. Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues , 1990, International journal of cancer.